Td-8954 clinical trials
Also written TAK-954 and TD-8954.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses td-8954 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Takeda (6) · Millennium Pharmaceuticals, Inc. (3) · Theravance Biopharma (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses td-8954 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After SurgeryCompletedPhase 2TakedaNCT03827655Written as TAK-954How we know
- Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis ParticipantsCompletedPhase 2TakedaNCT03281577Written as TAK-954How we know
- A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954CompletedPhase 1TakedaNCT03296787Written as TAK-954How we know
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03870555Written as TAK-954How we know
- A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding IntoleranceCompletedPhase 1/2TakedaNCT01953081Written as TD-8954How we know
- A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954CompletedPhase 1TakedaNCT03277274Written as TAK-954How we know
- TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)TerminatedPhase 2Millennium Pharmaceuticals, Inc.NCT03477903Written as TAK-954How we know
- A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT03500224Written as [14C]-TAK-954How we know
- A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult ParticipantsCompletedPhase 1TakedaNCT03173170Written as TAK-954How we know
- A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy SubjectsTerminatedPhase 1Theravance BiopharmaNCT01644240Written as TD-8954How we know
Codes
What other systems call td-8954 · ClinicalTrials.gg INT006293
- UNII (FDA) 35F0Y2W16QFELCISETRAGConfirmed FDA, Wikidata
- Wikidata Q27088952td-8954Confirmed FDA, Wikidata
- DrugBank DB12725One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 35F0Y2W16Q | FELCISETRAG | Confirmed FDA, Wikidata |
| Wikidata | Q27088952 | td-8954 | Confirmed FDA, Wikidata |
| DrugBank | DB12725 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.